NEW YORK, NY / ACCESSWIRE / September 21, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Eastman Kodak Company (NYSE:KODK)
If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/eastman-kodak-company-loss-submission-form?prid=9466&wire=1
Lead Plaintiff Deadline: October 13, 2020
Class Period: July 27, 2020 - August 11, 2020
According to a filed complaint, defendants failed to disclose that the Company had granted its Executive Chairman, James Continenza, and several other Company insiders millions of dollars' worth of stock options immediately prior to the Company publicly disclosing that it had received the $765 million loan, which Defendants knew would cause Kodak's stock to immediately increase in value once the deal was announced. In addition, while in possession of this material non-public information, Continenza and other Company insiders purchased tens of thousands of the Company's shares immediately prior to the announcement, again at prices that they knew would increase exponentially once news of the loan became public.
Lexinfintech Holdings, Ltd. (NASDAQ:LX)
If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/lexinfintech-holdings-ltd-loss-submission-form?prid=9466&wire=1
Lead Plaintiff Deadline: November 9, 2020
This lawsuit is on behalf of shareholders who purchased or otherwise acquired: (a) Lexin American depositary shares pursuant and/or traceable to the Company's initial public offering conducted on or about December 21, 2017; or (b) Lexin securities between December 21, 2017 and August 24, 2020.
Allegations against LX include that: (1) LexinFintech reported artificially low delinquency rates by giving borrowers in default new funds to make payments; (2) the Company's business model exposes shareholders to enormous losses by prioritizing Chinese lenders for off-balance-sheet loans; (3) the Company exaggerated its user base; (4) the Company was facilitating direct peer to peer lending contrary to Chinese law; (5) the Company engaged in undisclosed related party transactions; (6) the Company lacked adequate internal controls; and (7) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Odonate Therapeutics, Inc. (NASDAQ:ODT)
If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/odonate-therapeutics-inc-loss-submission-form?prid=9466&wire=1
Lead Plaintiff Deadline: November 16, 2020
Class Period: December 7, 2017 - April 21, 2020
Allegations against ODT include that: (i) the Company's orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel's commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more, contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong